- Home
- RGNX vs HUMA Comparison
RGNX vs HUMA Comparison
Compare RGNX & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- HUMA
- Stock Information
- Founded
- RGNX 2008
- HUMA 2004
- Country
- RGNX United States
- HUMA United States
- Employees
- RGNX N/A
- HUMA N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- HUMA Health Care
- Exchange
- RGNX Nasdaq
- HUMA Nasdaq
- Market Cap
- RGNX 424.8M
- HUMA 356.8M
- IPO Year
- RGNX 2015
- HUMA N/A
- Fundamental
- Price
- RGNX $8.17
- HUMA $2.21
- Analyst Decision
- RGNX Strong Buy
- HUMA Strong Buy
- Analyst Count
- RGNX 8
- HUMA 7
- Target Price
- RGNX $31.75
- HUMA $13.00
- AVG Volume (30 Days)
- RGNX 542.3K
- HUMA 3.8M
- Earning Date
- RGNX 08-07-2025
- HUMA 08-19-2025
- Dividend Yield
- RGNX N/A
- HUMA N/A
- EPS Growth
- RGNX N/A
- HUMA N/A
- EPS
- RGNX N/A
- HUMA N/A
- Revenue
- RGNX $156,718,000.00
- HUMA $517,000.00
- Revenue This Year
- RGNX $327.08
- HUMA N/A
- Revenue Next Year
- RGNX N/A
- HUMA $936.09
- P/E Ratio
- RGNX N/A
- HUMA N/A
- Revenue Growth
- RGNX 80.70
- HUMA N/A
- 52 Week Low
- RGNX $5.04
- HUMA $1.15
- 52 Week High
- RGNX $13.48
- HUMA $8.72
- Technical
- Relative Strength Index (RSI)
- RGNX 45.17
- HUMA 43.55
- Support Level
- RGNX $8.27
- HUMA $2.19
- Resistance Level
- RGNX $9.32
- HUMA $2.39
- Average True Range (ATR)
- RGNX 0.49
- HUMA 0.18
- MACD
- RGNX -0.04
- HUMA -0.03
- Stochastic Oscillator
- RGNX 20.16
- HUMA 10.00
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.